23Dec 2019

DIAGNOSTIC, THERAPEUTIC AND EVOLUTIONARY CHARACTERISTICS OF NASOPHARYNGEAL CANCER MANAGED WITH VMAT IN DEPARTMENT OF RADIOTHERAPY, MOHAMED V MILITARY TEACHING HOSPITAL - RABAT IN MOROCCO

  • Service De Radiotherapie, Hopital Militaire Dinstruction Mohammed - V, Universite Mohammed V, Rabat, Maroc
  • Service De Radiotherapie, Institut National Doncologie, Rabat, Maroc
Crossref Cited-by Linking logo

  • Abstract
  • Keywords
  • References
  • Cite This Article as
  • Corresponding Author

Purpose: The aim of this study was to report the experience of Military Teaching Hospital Mohamed V (MTHM V) in the management of NPC treated with volumetric modulated arc therapy (VMAT) Materials and Methods: This is a retrospective study conducted between January 2013 and December 2017. All patients with a nasopharyngeal cancer were included. Patients who had distant metastasis at the time of diagnosis were excluded. The volumetric arc therapy modulation of intensity (VMAT) is the technique radiotherapy used in all our patients. Results: one hundred and one (101) patients with nasopharyngeal cancer were treated in our department. The average age was 42.95?16.36. The predominant histological type is undifferentiated carcinoma (UCNT) in 93 % of cases. Tumors were classified according to the American Joint Committee on Cancer (AJCC) classification of 2010 in Stage I : 1%, Stage II in 10.9%, Stage III in 45.5%, Stage IVa in 32.7% and stage IVb in 9.9%. The treatment consisted of neoadjuvant chemotherapy followedby concomitant radio chemotherapy (RCC) at 79.2 % of patients, an RCC immediately in 12.8 % of cases and 8 % of patients received neoadjuvant chemotherapy followed by exclusive radiotherapy. The therapeutic tolerance was good with 16.8% of acute radiomucite Grade 3, 8.9% of acute dermatitis Grade 3 and no complication Grade 4. The overall survival was 98.8% and 84.8% at 2 and 5 years respectively, and the PFS was 85.6% and 76.8% at 2 and 5 years, respectively. N3 and time to relapse were significant in multivariate analysis for OS. Neoadjuvant chemotherapy and N3 were significant in multivariate analysis for PFS. Conclusion: volumetric modulated arc therapy with concurrent chemoradiotherapy with additional neoadjuvant chemotherapy has good response and outcomes. Our findings are in good accordance with other series but further large studies are warranted to improve prognostic of this potentially curable malignancy.

  1. Chua ML, Wee JT, Hui EP, Chan AT. Nasopharyngeal carcinoma. Lancet 2016; 387:1012.
  2. Chang ET, Adami HO. The enigmatic epidemiology of nasopharyngeal carcinoma.?Cancer Epidemiol Biomarkers Prev.?2006;15:1765?77.
  3. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012.?Int J Cancer.?2015;136:E359?86.
  4. Barnes L, Eveson JW, Reichart P, Sidransky D. Pathology and Genetics of Head and Neck Tumours. In: World Health Organization Classification of Tumors, IARC Press, Lyon 2005.
  5. Zhang L, Zhao C, Ghimire B, et al. The role of concurrent chemoradiotherapy inthe treatment of locoregionally advanced nasopharyngeal carcinoma among endemic population: a meta-analysis of the phase iii randomized trials. BMC Canc. 2010;10:558.
  6. Adelstein D, Gillison ML, Pfister DG, et al. NCCN guidelines insights: head and neck cancers, version 2.2017. J NatlComprCancNetw. 2017;15(6):761?770. doi:10.6004/jnccn.2017.0101
  7. Chua DTT, Ma J, Sham JST, et al. Long-term survival after cisplatin- based induction chemotherapy and radiotherapy for nasopharyngeal carcinoma: a pooled data analysis of two phase III trials. J Clin Oncol Of J Am SociClin Oncol. 2005;23(6):1118?1124. doi:10.1200/ JCO.2005.12.081
  8. Pow EH, Kwong DL, McMillan AS, et al. Xerostomia and quality of life after intensity-modulated radiotherapy vs. conventional radiotherapy for early- stage nasopharyngeal carcinoma: initial report on a randomized controlled clinical trial. Int J RadiatOncolBiolPhys 2006;66(4):981?91.
  9. Aiken RD. Neurologic complications of head and neck cancers. SeminOncol 2006; 33:348.
  10. Hsu MM, Tu SM. Nasopharyngeal carcinoma in Taiwan. Clinical manifestations and results of therapy. Cancer 1983; 52:362.
  11. Vokes EE, Liebowitz DN, Weichselbaum RR. Nasopharyngeal carcinoma. Lancet 1997; 350:1087.
  12. Altun M, Fandi A, Dupuis O, et al. Undifferentiated nasopharyngeal cancer (UCNT): current diagnostic and therapeutic aspects. Int J RadiatOncolBiolPhys 1995; 32:859.
  13. Pathology and genetics of head and neck tumors. In: World Health Organization Classification of Tumours, Barnes L, Eveson JW, Reichart P, Sidransky D (Eds), IARC Press, Lyon 2005.
  14. Al-Sarraf M, LeBlanc M, Giri PG, Fu KK, Cooper J, Vuong T, Forastiere AA,Adams G, Sakr WA, Schuller DE, Ensley JF: Chemoradiotherapy versusradiotherapy in patients with advanced nasopharyngeal cancer: phase IIIrandomized Intergroup study 0099. J ClinOncol 1998, 16:1310?1317.
  15. Wee J, Tan EH, Tai BC, Wong HB, Leong SS, Tan T, Chua ET, Yang E, Lee KM, Fong KW, Tan HSK, Lee KS, Loong S, Sethi V, Chua EJ, Machin D: Randomized trial of radiotherapy vs concurrent chemoradiotherapy followed by adjuvant chemotherapy in patients with American joint committee on cancer/international union against cancer stage III and IV nasopharyngeal cancer of the endemic variety. J ClinOncol 2005, 23:6730?6738.
  16. Lee AW, Lau WH, Tung S, Chua DT, Chappell R, Xu L, Siu L, Sze WM, Leung TW, Shams JS, Ngan RK, Law SC, Yau TK, Au JS, OSullivan B, Pang ES OSK, Au GK, Lau JT: Preliminary results of a randomized study on therapeutic gain by concurrent chemotherapy for regionally advanced nasopharyngeal carcinoma: NPC-9901 trial by the Hong Kong nasopharyngeal cancer study group. J ClinOncol 2005, 23:6966?6975.
  17. Chan AT, Teo PM, Ngan RK: Concurrent chemotherapy-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma:progression-free survival analysis of a phase III randomized trial. J ClinOncol 2002, 20:2038?2044.
  18. Lin JC, Jan JS, Hsu C, Liang WM, Jiang RS, Wang WY: Phase III study of concurrent chemoradiotherapy versus radiotherapy alone for advanced nasopharyngeal carcinoma: positive effect on overall survival and progression-free survival. J ClinOncol 2003, 21:631?637.
  19. Kwong DL, Sham JS, Au GK, Chua DT, Kwong PW, Cheng AC, Wu PM, Law MW, Kwok CC, Yau CC, Wan KY, Chan RT, Choy DD: Concurrent and adjuvant chemotherapy for nasopharyngeal carcinoma: a factorial study. J ClinOncol 2004, 22:2643?2653.
  20. Baujat B, Audry H, Bourhis J, Chan AT, Onat H, Chua DT, Kwong DL, Al-Sarraf M, Chi KH, Hareyama M, Leung SF, Thephamongkhol K, Pignon JP: Chemotherapy in locally advanced nasopharyngeal carcinoma: an individual patient data meta-analysis of eight randomized trials and 1753 patients. Int J RadiatOncolBiolPhys 2006, 64:47?56.
  21. Chitapanarux I, Lorvidhaya V, Kamnerdsupaphon P, et al. Chemoradiation comparing cisplatin versus carboplatin in locally advanced nasopharyngeal cancer: randomised, non-inferiority, open trial. Eur J Cancer 2007; 43:1399.
  22. Kam MK, Chau RM, Suen J, Choi PH, Teo PM: Intensity-modulated radiotherapy in nasopharyngeal carcinoma: dosimetric advantage over conventional plans and feasibility of dose escalation. Int J RadiatBiolOncolPhys 2003, 56:145?157.
  23. Xia P, Fu KK, Wong GW, Akazawa C, Verhey LJ: Comparison of treatment plans involving intensity-modulated radiotherapy for nasopharyngeal carcinoma. Int J RadiatOncolBiolPhys 2000, 48:329?337.
  24. Kristensen CA, Kjaer-Kristoffersen F, Sapru W, Berthelsen AK, Loft A, Specht L: Nasopharyngeal carcinoma. Treatment planning with IMRT and 3D conformal radiotherapy. ActaOncol 2007, 46:214?220.
  25. M?nter MW, Karger CP, Hoffner G, Hof H, Thilmann C, Rudat V, NillS,Wannenmacher M, Debus J: Evaluation of salivary gland function aftertreatment of head-and-neck tumors with intensity-modulatedradiotherapy by quantitative pertechnetatescintigraphy. Int J RadiatOncolBiolPhys 2004, 58:175?184.
  26. M?nter MW, Hoffner S, Hof H, Herfarth KK, Haberkorn U, Rudat V, Huber PE, Debus J, Karger CP: Changes in salivary gland function after radiotherapy of head and neck tumors measured by quantitative pertechnetatescinitgraphy: comparison of intensity-modulated radiotherapy and conventional radiation therapy with and without Amifostine. Int J RadiatOncolBiolPhys 2007, 67:651?659.
  27. Wolden SL, Chen WC, Pfister DG, Kraus DH, Berry SL, Zelefsky MJ: Intensitymodulatedradiation therapy (IMRT) for nasopharynx cancer: update of the memorial Sloan-Kettering experience. Int J RadiatOncolBiolPhys
  28. 2006, 64:57?62.
  29. Lee N, Xia P, Quivey JM, Sultanem K, Poon I, Akazawa C, Akazawa P,
  30. Weinberg V, Fu KK: Intensity-modulated radiotherapy in the treatment of nasopharyngeal carcinoma: an update of the USCF experience. Int J RadiatOncolBiolPhys 2002, 53:12?22.
  31. Kwong DL, Sham JS, Leung LH, Cheng AC, Kwong PW, Lui WM, Yau CC, Wu PM, Wei W, Au G: Preliminary results of radiation dose escalation for locally advanced nasopharyngeal carcinoma. Int J RadiatOncolBiolPhys2006, 64:374?381.
  32. Kam MK, Teo PM, Chau RM, Cheung KY, Choi PH, Kwan WH, Leung SF, Zee B, Chan AT: Treatment of nasopharyngeal carcinoma with intensitymodulatedradiotherapy: the Hong Kong experience. Int J RadiatOncol
  33. Tham IW, Hee SW, Yeo RM, Salleh PB, Lee J, Tan TW, Fong KW, Chua ET, Wee JT: Treatment of nasopharyngeal carcinoma using intensitymodulatedradiotherapy ? the national cancer center Singapore experience. Int J RadiatOncolBiolPhys 2009, 75:1481?1486.
  34. Lee N, Harris J, Garden AS, Straube W, Glisson B, Xia P, Bosch W, Morrison WH, Quivey J, Thorstad W, Jones C, Kian Ang K: Intensity-modulated radiation therapy with or without chemotherapy for nasopharyngeal
  35. carcinoma:radiation therapy oncology group phase II trial 0225. J ClinOncol 2009, 27:3684?3690.
  36. Peponi E, Glanzmann C, Kunz G, Renner C, Tomuschat K, Studer G:
  37. Simultaneous integrated boost intensity-modulated radiotherapy (SIB-IMRT) in nasopharyngeal cancer. StrahlentherOnkol 2010, 186:135?142.
  38. Cannon DM, Lee NY: Recurrence in region of spared parotid gland after definitive intensity-modulated radiotherapy for head and neck cancer. Int J RadiatOncolBiolPhys 2008, 70:660?665.

[Khalid Hadadi, Mohcine Hommadi, Abdelhak Maghous, Maroa Belemlih, Noha Zaghba, El-Amin Marnouch, Khalid Andaloussi Saghir, Mohamed Elmarjany, Hassan Sifat and Hamid Mansouri (2019); DIAGNOSTIC, THERAPEUTIC AND EVOLUTIONARY CHARACTERISTICS OF NASOPHARYNGEAL CANCER MANAGED WITH VMAT IN DEPARTMENT OF RADIOTHERAPY, MOHAMED V MILITARY TEACHING HOSPITAL - RABAT IN MOROCCO Int. J. of Adv. Res. 7 (Dec). 708-718] (ISSN 2320-5407). www.journalijar.com

abdelhak maghous
radiation oncologist

DOI:

Article DOI: 10.21474/IJAR01/10199      
DOI URL: https://dx.doi.org/10.21474/IJAR01/10199

Download Full Paper

Download PDF No. of Downloads: 24 | No. of Views: 85